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PK11195 Increases Anxiety Like Behaviors in the Open Field 
Introduction:
Anxiety is one of the most common mental illnesses in 
the US.  Signaling between regions of the brain can be 
corrupted causing stress related behaviors.  Medications 
that help treat these behaviors target GABA receptors in 
an inhibitory manner.  However, these medications only 
work for a period of time.  The likelihood of being free 
of these medications becomes uncertain.  Another 
approach is a protein called translocator protein.  TSPO, 
once known as peripheral benzodiazepine receptor is 
known to mediate anxiety related behaviors through 
the synthesis of neurosteriods.  While TSPO may 
mediate these behaviors, its mechanism is not well 
known.  Ligand PK11195 was used to evaluate behaviors 
in animal models using the open field task.  
Methods:
Open field task- four mice were able to move in their 
own separate (43.5 cm) for sixty minutes.  Two of the 
mice received the treatment of PK11195 and two 
received a saline solution.
Results:
While ligands that have an affinity for TSPO can produce 
anxiolytic effects, PK11195 showed the opposite effect.  
Animal models that were injected with the novel ligand 
did not habituate to their environment over the given 
time of the open field task. This suggests that the action 
of TSPO was blocked by PK11195, thus enhancing anxiety 
like behavior.
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Discussion:
Anxiety effects many individuals today.  Many of the medications 
that help treat this are only temporary and are not ideal for 
normal living.  While these medications are still used, there may 
be better ways in treating anxiety.  Translocator protein may be 
able to aid in the effects of anxiety related disorders through the 
synthesis of neurosteriods.  While TSPO may help, its effect in 
mediating the disorder may depend on the ligand that is bound 
to it.  This may be a step in creating better mechanisms in which 
to treat anxiety related disorders.
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